Drugs Health Pharma

Pfizer, BioNTech gets EMA marketing nod for variant Covid-19 vaccine

The European Medicines Agency has allowed marketing authorisation for the Covid-19 variant vaccine made by Pfizer and BioNTech SE for children aged six.

Read More
Drugs Health Pharma

BioNTech expects revenue to be lower in 2023 as Covid-19 vaccine sales fall

HQ Team October 16, 2023: Germany’s  BioNTech announced its partner Pfizer Inc.’s write-offs for inventory and other charges related to the Covid-19 Comirnaty.

Read More
Drugs Health Pharma

CDC, ECDC differ on vaccination program for fall-winter season

HQ Team September 13, 2023: The US national public agency has recommended a COVID-19 vaccination policy where updated shots are given starting from.

Read More
Drugs Health Pharma

USFDA green lights vaccines to fight COVID-19 variants in flu season

HQ Team September 12, 2023: The US drug and medicine regulator, the FDA, approved COVID-19 vaccines made by Moderna Inc., Pfizer Inc., and  BioNTech.

Read More
Drugs Health Medical Pharma

Arbutus drags Pfizer, BioNTech to court over patent infringements

HQ Team April 5, 2023: Arbutus Biopharma Corporation and Genevant Sciences filed a lawsuit in a US court seeking compensation for Pfizer and BioNTech’s unlicensed use.

Read More
Drugs Medical Pharma

BioNTech, Duality Biologics sign $1.5 billion pact for cancer drugs

HQ Team April 3, 2023: BioNTech SE and Duality Biologics (Suzhou) have signed a $1.5 billion deal to develop and commercialise two cancer.

Read More
Drugs Medical Pharma

BioNTech in one million euro push for research on drugs

BioNTech, a Germany-based biotechnology company, is expected to spend between 2.4 million euros and 2.6 million euros on research this year compared with.

Read More
Drugs Medical Pharma

FDA nod for Pfizer-Biotech vaccine booster for children

The FDA cleared the emergency use of bivalent Pfizer-Biotech COVID-19 vaccine for a single dose booster in children aged six months to four.

Read More
Drugs Pharma

BioNTech to invest $43 million in new mRNA facility

BioNTech SE, an immunotherapy company, will invest $43 million in a new facility in Germany to make a vital ingredient for its mRNA.

Read More
Medical Pharma

BioNTech signs MoU with UK govt to start clinical trials for mRNA cancer vaccine

BioNTech signs MoU with the British government to start mRNA cancer trials

Read More
X